Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple sclerosis

S G Lynch1, J W Rose

  • 1University of Kansas Medical School, Kansas City, USA.

Disease-A-Month : DM
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) is a chronic autoimmune disease with variable symptoms. Current treatments focus on managing relapses and symptoms, with new therapies under investigation to reduce disease progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Examining changes in neurofilament light chain following a behavioral weight loss intervention for adults with multiple sclerosis and obesity.

Multiple sclerosis and related disorders·2025
Same author

Body metrics are associated with clinical, free-living, and self-report measures of mobility in a cohort of adults with obesity and multiple sclerosis.

Multiple sclerosis and related disorders·2023
Same author

Spectroscopic gas detection using a Bragg grating - stabilized external cavity laser, custom written in planar integrated silica-on-silicon.

Optics express·2019
Same author

The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics.

Multiple sclerosis and related disorders·2015
Same author

Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T.

Multiple sclerosis (Houndmills, Basingstoke, England)·2010
Same author

Numerical solution of the scalar-wave equation for inhomogeneous cylindrical dielectric waveguides.

Optics letters·2009
Same journal

Disturbances due to cold.

Disease-a-month : DM·2026
Same journal

GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.

Disease-a-month : DM·2026
Same journal

GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.

Disease-a-month : DM·2026
Same journal

Periodontal disease and diabetic kidney disease: A comprehensive analysis.

Disease-a-month : DM·2026
Same journal

Foreword for Glucagon-like peptide-1 receptor agonists (GLP-1) and its promise for potential benefits.

Disease-a-month : DM·2026
Same journal

Foreword for insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

Disease-a-month : DM·2026
See all related articles

Area of Science:

  • Neurology
  • Immunology
  • Chronic Disease Research

Background:

  • Multiple sclerosis (MS) is a chronic, autoimmune disease affecting young adults.
  • Its etiology involves unknown genetic and environmental factors.
  • MS presents with unpredictable neurological symptoms over many years.

Purpose of the Study:

  • To summarize the current understanding of multiple sclerosis.
  • To outline diagnostic methods and treatment strategies for MS.
  • To highlight ongoing research for new MS therapies.

Main Methods:

  • Diagnosis relies on clinical observation, neurological exams, and tests like MRI, lumbar puncture, and evoked potentials.
  • Treatment includes supportive care, corticosteroids for relapses, and symptomatic management.

Related Experiment Videos

  • Immunosuppressants and disease-modifying therapies like interferon-beta are used.

    • Main Results:

    • Interferon-beta can reduce relapse frequency in relapsing-remitting MS.
    • New agents, including copolymer 1 and interferon-beta 1a, are under FDA review.
    • Immunosuppressive agents are used for chronic progression, with further research ongoing.

    Conclusions:

    • MS management involves a combination of supportive, symptomatic, and disease-modifying treatments.
    • Ongoing research aims to improve treatment efficacy and address chronic progression.
    • Early diagnosis and tailored treatment are crucial for managing MS.